Momenta Pharmaceuticals to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference

Globe Newswire 2-Jan-2019 8:00 AM

CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that Craig Wheeler, President and CEO, will present at the 37th Annual J.P. Morgan Healthcare Conference.  The presentation is scheduled for Wednesday, January 9, 2019 at 10:00 a.m. PT (1:00 p.m. ET).

Following the presentation, management will participate in a question and answer session at 10:30 a.m. PT (1:30 p.m. ET).

A webcast of the presentation will be available live on the "Investors" section of the company's website located at www.momentapharma.com.  A replay of the presentation will be posted on the Momenta website approximately one hour after the event.

About Momenta
Momenta is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases. Momenta's lead product candidate, M281, is a potentially best-in-class anti-FcRn antibody; M254, is a hyper-sialylated human immunoglobulin (hsIgG) designed as a high potency alternative to intravenous immunoglobulin (IVIg); and M230 (CSL730), is a potential first-in-class novel recombinant Fc multimer being developed in collaboration with CSL. Momenta also has a focused pipeline of two biosimilar candidates: M923, Momenta's wholly-owned proposed biosimilar to HUMIRA^®, and M710, a proposed biosimilar to EYLEA^® being developed in collaboration with Mylan.  Momenta's two FDA-approved complex generic products, enoxaparin sodium injection and Glatopa^® (glatiramer acetate injection), are marketed by its collaboration partner, Sandoz.

To learn more about Momenta, please visit www.momentapharma.com, which does not form a part of this press release.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Contact:
Young Kwon
Momenta Pharmaceuticals
1-617-395-4964
IR@momentapharma.com